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Abstract
Background: Despite advances in radical esophagectomies and adjuvant therapy, the postoperative prognosis in
esophageal squamous cell carcinoma (ESCC) patients remains poor. The aim of this study was to identify a
molecular signature to predict postoperative favorable outcomes in patients with ESCC.
Methods: As a training data set, total RNA was extracted from formalin-fixed paraffin-embedded samples of
surgically removed specimens from 19 ESCC patients who underwent curative esophagectomy. The expression of
microRNA (miRNA) was detected using a miRNA oligo chip on which 885 genes were mounted. As a validation
data set, we obtained frozen samples of surgically resected tumors from 12 independent ESCC patients and the
expression of miR-574-3p was detected by quantitative real-time PCR.
Results: Our microarray analysis in the training set patients identified three miRNAs (miR-574-3p, miR-106b, and
miR-1303) and five miRNAs (miR-1203, miR-1909, miR-204, miR-371-3p, miR-886-3p) which were differentially
expressed between the patients with (n = 14) and without (n = 5) postoperative tumor relapse (p < 0.01 and
p < 0.05, respectively). Higher expression of miR-574-3p, which showed the most significant association with non-relapse
(p = 0.001), was associated with favorable overall survival (p = 0.016). Real-time PCR experiments on the validation set
patients confirmed that higher expression of miR-574-3p was associated with non-tumor relapse (p = 0.029)
and better overall survival (p = 0.004).
Conclusions: Our results suggest that the aberrant expression of the miRNAs identified in this study plays key
roles in the progression of ESCC. miR-574-3p was suggested to have a tumor suppressor effect, and thus, to be a
predictor of postoperative outcome in patients with ESCC.
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Background
Recent progress in radical esophagectomies and peri-
operative adjuvant therapy has facilitated an improved
postoperative prognosis, even in patients with advanced
esophageal squamous cell carcinoma (ESCC) [1]. However,
many of the patients still exhibit postoperative tumor recur-
rence with a 5-year progression-free survival rate of about
40 % [2, 3]. Therefore, innovative strategies to predict early
postoperative tumor relapse may provide us with a more
accurate diagnosis to determine operative indications.
MicroRNAs (miRNAs) are small, single-stranded, non-
coding RNAs that play a key role in the initiation and
progression of cancer through the post-transcriptional
regulation of gene expression [4]. They have also been
reported to be potential biomarkers for therapeutic
effects and prognoses in cancer patients [5].
In the present study, we investigated the expression
profiles of miRNAs in surgically removed ESCC speci-
mens to identify relapse-associated miRNAs.
Methods
Patients and surgical specimens
We selected eighty-three consecutive ESCC patients
who underwent curative surgery in Toyama University
Hospital between 1991 and 2008, excluding 16 cases
who died of other causes within 5 years after surgery.
Then, we obtained formalin-fixed paraffin-embedded
(FFPE) samples of the tumors and their normal counter-
parts, with adequate tissue size from 36 cases as a train-
ing data set. In addition, we obtained frozen samples of
surgically resected tumors and their normal counter-
parts, which had been kept at −80 °C, from 12 independ-
ent ESCC patients who received curative surgery in our
hospital between 2008 and 2010 to use as a validation
data set. The observation period was calculated from the
date of surgery until the patient succumbed to the
disease or the last follow-up contact. All cases were
staged according to the International Union Against
Cancer TNM Classification 7th edition [6].
RNA extraction from FFPE specimens
Sections (10 μm) were prepared from each FFPE
specimen. Paraffin was removed by xylene treatment,
and the tissues were then washed with ethanol twice to
remove the xylene. The tissues were treated with pro-
teinase K at 37 °C overnight. Following centrifugation,
the supernatant was processed with a silica-based spin
column (Toray Industries, Japan) in order to obtain puri-
fied total RNA. The degrees of RNA cross-linking and
RNA degradation were analyzed by electrophoresis using
an Agilent 2100 Bioanalyzer (Agilent Technologies, Santa
Clara, CA, USA).
miRNA assays using microarray
miRNA profiling was examined using a Toray 3D-Gene®
miRNA oligo chip (Toray Industries), on which 885
genes were mounted. The detailed procedure for this
experiment has been described previously [7]. The
expression level of each miRNA was normalized using the
median signal strength for the entire gene in each chip.
RNA extraction from frozen specimens and quantitative
RT-PCR analysis for microRNA s
Frozen specimens were obtained from surgically re-
moved esophagus with Lugol’s solution staining. Tumor
samples were cut from main part of the tumor, and
normal tissues from mucosal epithelia with positive
Lugol staining, more than 5 cm distant from the tumor
edge. The sections were also confirmed by a board-
certified pathologist. Total RNA was extracted from
frozen specimens using the TRIzol Reagent (Invitrogen,
Carlsbad, CA, USA) according to a standard protocol.
cDNA was prepared from total RNA samples using the
Taq Man microRNA reverse transcription kit on the ABI
Prism 7000 real-time PCR system, according to the
manufacturer’s instructions (Applied Biosystems). Prede-
signed Taq Man microRNA assays for hsa-miR-574-3p
(Assay ID 002349) and RNU6B (Assay ID 001093) were
purchased from Applied Biosystems. qRT-PCR was
performed using a Taq Man universal PCR master mix,
according to the manufacturer’s protocol (Applied
Biosystems). The microRNA quantities were analyzed in
duplicate and normalized against U6B as an internal
control. The tumor-to-normal ratio (T/N ratio) was
calculated based on the miRNA expression levels in each
tumor and the corresponding normal counterpart.
Statistical analysis
All analyses were carried out with JMP 9.0 software (SAS
Institute Inc., Cary, NC, USA). The average expression
level (T/N ratio) of each miRNA was calculated and log2-
transformed. Differences in miRNA expression levels
between two variables were analyzed by the Student’s t
test and logistic regression analysis.
Hierarchical clustering analysis was performed with
non-supervised Ward’s method.
The relationship between the expression of miRNAs
and various clinicopathological factors were assessed using
the chi-squared test. The Kaplan-Meier method was used
to estimate patient survival. Differences in postoperative
outcome for the expression of the selected miRNAs were
analyzed using the log-rank test. p < 0.01 was used for
significance in microarray analysis with the Student’s t test
and logistic regression analysis, while p < 0.05 was used
for significance in the chi-squared test and log-rank test.
We constructed receiver operating characteristic (ROC)
curves and calculated the area under the curve (AUC) to
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evaluate the specificity and sensitivity as a postoperative
prognostic predictor.
Results
Patient information and tumor characteristics
For a training data set, in 36 cases from which we
extracted total RNA from archival FFPE samples, we
obtained high-quality RNA of both tumors and corre-
sponding normal esophageal epithelia from 19 patients.
The clinical information and tumor characteristics of
these patients are shown in Table 1. Among the 19
patients, five patients achieved 5-year disease-free
survival with an observation period (average ± SD) of
138.7 ± 45.1 months, while 14 patients died of tumor re-
lapse at an observation period (average ± SD) of 14 ±
9.2 months after surgery. These two groups were
referred to as the non-relapse group (n = 5) and relapse
group (n = 14). All patients in the relapse group and
three of the five patients in the non-relapse group were
males. There were no statistical differences between the
relapse and non-relapse group in the other clinicopatho-
logical characteristics such as age, tumor location, histo-
logical grade, pathologic tumor depth, lymph node
metastasis, distant metastasis, TNM stage, lymphatic
vessel invasion, or venous invasion. All 19 patients
underwent radical surgery with no residual tumors (R0).
None of the five patients in the non-relapse group
received preoperative adjuvant therapy, while three of
the 14 (21.4 %) in the relapse group received preopera-
tive chemo- or chemo-radio therapy. One of the five
(20.0 %) patients in the non-relapse group and seven of
the 14 (50.0 %) patients in the relapse group received
postoperative chemo- or chemo-radio therapy. The
postoperative observation period (average ± SD) in the
non-relapse and relapse groups were 138.7 ± 45.1 and
14 ± 9.2 months, respectively (p < 0.001). In the relapse
group, the duration between surgery and tumor relapse
(average ± SD) was 10.0 ± 8.4 months. The sites of
tumor relapse were; liver: 5, lymph node: 2, local
recurrence: 1, liver and lymph node: 4, lymph nodes
and local recurrence: 2.
For the validation data set, we obtained high-quality
RNA from both tumors and corresponding normal
esophageal epithelia from 12 ESCC patients. Eight
patients were male and four patients were female, and
the average age (average ± SD) was 63.6 ± 9.9 years. All
12 patients underwent radical surgery with no residual
tumors (R0). Eight out of 12 patients achieved a 5-year
disease-free survival with an observation period (aver-
age ± SD) of 64.6 ± 18.3 months, while four patients died
of tumor relapse at an observation period (average ± SD)
of 51.2 ± 27.4 months after surgery (p = 0.049, Table 4).
These two groups were referred to as the relapse group
(n = 4) and non-relapse group (n = 8).
Table 1 Clinicopathological characteristics of the 19 patients in
the training data set
Non-relapse Relapse p value
Case number 5 14
Age (mean ± SD) 68.4 ± 10.7 61 ± 9.6 0.111
Gender
Male 3 14 0.012
Female 2 0
Tumor location
Upper/middle thoracic 1 7 0.244
Lower thoracic 4 7
Histological grade
Well/moderate 4 13 0.421
Poorly 1 1
Pathologic tumor depth
T1-2 3 3 0.111
T3-4 2 11
Lymph node metastasis
N0 2 3 0.418
N1-3 3 11
Distant metastasis
M0 5 14 –
M1 0 0
TNM stage (IUAC TNM Classification 7th edition)
1–2 3 4 0.211
3–4 2 10
Lymphatic vessel invasion
Negative 2 3 0.418
Positive 3 11
Venous invasion
Negative 3 4 0.211
Positive 2 10
Curability
R0 5 14 –
R1 0 0




Postoperative chemotherapy 0 2 –
Postoperative CRT 1 5
Observation period (month, mean ± SD) 138.7 ± 45.1 14 ± 9.2 <0.001
Duration between surgery and tumor
relapse
– 10 ± 8.4 –
Type of tumor relapse
Liver (H) 0 5
Lymph node (Ly) 0 2
Local (L) 0 1
H + Ly 0 4
Ly + L 0 2
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The expression of miRNAs in FFPE samples of ESCC
tumors detected by microarray
In the 885 miRNAs assessed using the miRNA oligo
chip, the signals of 320 miRNAs were detected in all
examined samples. Comparisons between the average
expression levels of miRNAs in the 19 ESCC tumors
and those in the 19 corresponding normal tissues re-
vealed that the expression of 10 miRNAs (miR-16,
miR-93, miR-200c, miR-15b, miR-25-3p, miR-34a,
miR-181a, miR-107, miR-103a, and miR-151a) were
more than twofold higher, while that of another 10
miRNAs (miR-133b, miR-513, miR-1224, miR-30c,
miR-1236, miR-378a, miR-550a, miR-675, miR-149,
and miR-1973) were more than twofold lower in the
tumors than in their normal counterparts with statis-
tical difference (Fig. 1a). The relationship between the
expression of these 20 miRNAs in the tumors (T/N ra-
tio) and clinicopathological features of the tumors
were summarized in Additional file 1: Table S1. The
higher expression of miR-200c correlated with pro-
gressed TNM Stage (p = 0.038) and postoperative tumor
relapse (p = 0.038). On the other hand, the expression of
the other 19 miRNAs in tumors did not show correlation
with clinicopathological characteristics of the patients.
Hierarchical clustering based on all 320 detected miRNAs
did not show any relationship between clusters and post-
operative tumor relapse (Fig. 1b).
Differentially expressed miRNAs between patients with
and without postoperative tumor relapse
When the expression (T/N ratio) of miRNAs was
compared between relapse (n = 14) and non-relapse
(n = 5) cases using two types of statistical method (t
test and logistic regression analysis), the lower ex-
pression of miR-574-3p and miR-106b, as well as
higher expression of miR-1303, correlated with post-
operative tumor relapse with statistical significance
(p < 0.01, Table 2). The Box-and-Whisker plots for
these three miRNAs were shown in Fig. 2a.
In addition, the lower expression of other four miR-
NAs (miR-1203, miR-1909, miR-204, miR-371-3p), and
higher expression of miR-886-3p, correlated with
Fig. 1 Expression of miRNAs in ESCC. a Twenty miRNAs that were expressed in ESCC tumors with more than a twofold difference compared with
corresponding normal counter parts. b Cluster analysis. The diagram shows the results of the hierarchical clustering of miRNAs and 19 samples.
Columns: 320 miRNAs that were detected in all 19 cases. Red represents a higher expression level; green represents a lower expression level. Rows:
samples. Cases 1–5 (highlighted in red) were non-relapse cases. Cases 6–19 were relapse cases
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postoperative tumor relapse (p < 0.05, Table 2). Based
on a ROC curve analysis to differentiate patients with
relapse from patients without relapse, the cut-off
value, the largest AUC value, sensitivity, and specifi-
city for the expression of the top three miRNAs are
shown in Table 3.
Based on the cut-off value listed in Table 3, the overall
survival rate of the patients with high expression of miR-
574-3p, low expression of miR-1303 were significantly
better (Fig. 2b, d). On the other hand, the expression of
miR-106b did not correlate with the overall survival rate
of the patients (Fig. 2c).
Table 2 Expression of miRNAs associated with postoperative tumor relapse
Non-Relapse (n = 5) Relapse (n = 14) t test Logistic regression analysis
Average SD Average SD p value p value
miR-574-3p 0.87 0.18 0.67 0.05 0.001 0.009
miR-106b 1.18 0.26 0.87 0.16 0.004 0.005
miR-1303 1.11 0.17 1.53 0.24 0.007 0.001
miR-1203 1.34 0.70 0.73 0.24 0.006 0.011
miR-1909 0.92 0.17 0.71 0.13 0.009 0.016
miR-204 1.10 0.35 0.76 0.23 0.016 0.033
miR-371-3p 1.27 0.31 0.94 0.25 0.021 0.019
miR-886-3p 0.90 0.49 1.49 0.55 0.037 0.033
Fig. 2 The relationship between the expression of miRNAs (miR-574-3p, miR-106b, and miR-1303) and patient outcome in the training cohort. a The
expression of miR-574-3p, miR-106b, and miR-1303 in non-relapse and relapse groups. b The association between the expression of miRNAs (miR-574-3p,
miR-106b, and miR-1303) and patient prognosis
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The expression of miR-574-3p, miR-106b and miR-1303 in
frozen samples of ESCC detected by quantitative RT-PCR
analysis
Compared with the corresponding normal esophageal
mucosa, the expression of miR-574-3p, miR-106b and
miR-1303 were upregulated in 8/12 (66.7 %), 11/12
(91.7 %), and 7/12 (58.3 %) of the validation set patients
(Fig. 3a–c). When the expression (T/N ratio) of miRNAs
was compared between relapse (n = 4) and non-relapse
(n = 8) cases, higher expression of miR-574-3p was in-
versely correlated with tumor relapse (p = 0.029), while
the expression of miR-106b and miR-1303 did not show
correlation with tumor relapse (Table 4). The Box-and-
Whisker plots for these three miRNAs are shown in
Fig. 4a.
The overall survival rate of the patients with high ex-
pression of miR-574-3p was significantly better than that
of those with low expression (p = 0.004), while the
expression of miR-106b and miR-1303 did not show
correlation with overall survival rate of the patients
(Fig. 4b–d).
Discussion
In the 320 miRNAs assessed using the miRNA oligo
chip, the expression of 20 miRNAs were aberrantly
expressed in the tumors compared with their normal
counterparts, with more than a twofold difference.
Among these 20 miRNAs, 13 miRNAs, such as miR-16
[8], miR-93 [9], miR-200c [10], miR-25-3p [11], miR-34a
[12], miR-181a [13], miR-107 [14], miR-103a [15], miR-
151a [16], miR-149 [17], miR-550a [18], miR-378a [19],
and miR-30c [20], have been associated with the malig-
nant potential of esophageal cancer.
In addition, the other seven miRNAs, such as miR-
15b-5p [21], miR-1973 [22], miR-675-3p [23], miR-
1236-3p [24], miR-1224-3p [25], miR-513a-5p [26],
and miR-133b [27], have been associated with the
malignant potential of other types of cancer.
These results indicated that the archival FFPE samples
were successfully used to identify differentially expressed
miRNAs in this study, and suggested the crucial roles of
Table 3 Cut-off value for predicting relapse analyzed using
receiver-operating characteristic (ROC) curves
Name Cut-off AUC Sensitivity Specificity
miR-574-3p 0.70 0.89 0.93 0.80
miR-106b 1.00 0.89 0.79 0.80
miR-1303 1.20 0.94 0.86 1.00
Fig. 3 The expression of miRNAs (miR-574-3p, miR-106b and miR-1303) in ESCC patients in the validation cohort. a The expression (T/N ratio) of
miR-574-3p in frozen samples of surgically removed ESCC specimens detected by RT-PCR. b The expression (T/N ratio) of miR-106b in frozen
samples of surgically removed ESCC specimens detected by RT-PCR. c The expression (T/N ratio) of miR-1303 in frozen samples of surgically
removed ESCC specimens detected by RT-PCR
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these miRNAs in the development and progression of
ESCC.
The expression profiles of miRNAs have been shown
to differentiate molecular subtypes in several types of
cancer, such as pancreatic cancer [28] and small cell car-
cinoma of the esophagus [29]. A previous report from
our laboratory has demonstrated that hierarchical cluster-
ing based on all 410 detected miRNAs showed two
discrete clusters in primary small cell carcinoma of the
esophagus, and these two clusters were identical to the
two patients groups, i.e., patients with and without post-
operative tumor relapse [29]. However, in this present
study, hierarchical clustering based on all 320 detected
miRNAs did not show a relationship between clusters and
postoperative tumor relapse, indicating the need to select
a specific gene set to predict postoperative outcomes.
All the 15 miRNAs that were significantly expressed
differentially between the relapse and non-relapse
groups (p < 0.05) have been reported to be either
oncogenes [18, 29–36], or tumor suppressors [37–42] in
various type of tumors.
In the list of miRNAs, the higher expression of miR-
574-3p, which showed the most significant inverse
association with postoperative tumor relapse (p = 0.001),
was linked with a significantly better overall survival rate
of the patients in the training set.
In the validation set of the patients, higher expres-
sion of miR-574-3p was inversely associated with
tumor relapse (p = 0.029) and a better overall sur-
vival rate (p = 0.004), further suggesting that the ab-
errant expression of the miRNAs identified in this
study plays key roles in the postoperative outcome
of ESCC.
miR-574-3p has been reported to be a tumor suppres-
sor miRNA in various cancers [43]. In gastric cancer, re-
duced expression of miR-574-3p in tumors and
inhibition of cell proliferation, migration, and invasion
in miR-574-3p-transfected cancer cells have been re-
ported [37]. In bladder cancer cells, miR-574-3p has
been reported to target mesoderm development candi-
date 1 (MESDC1) miRNA, subsequently inhibiting cell
proliferation, migration and invasion ability, and induced
cell apoptosis [44]. In prostate cancer, miR-574-3p was
Table 4 Clinicopathological characteristics of the 12 patients in
the validation set
Non-relapse Relapse p value
Case number 8 4
Age (mean ± SD) 63.0 ± 10.3 66.7 ± 8.0 0.425
Gender
Male 4 4 0.08
Female 4 0
Tumor location
Upper/middle thoracic 5 2 0.67
Lower thoracic 3 2
Histological grade
Well/moderate 7 2 0.16
Poorly 1 2
Pathologic tumor depth
T1-2 2 1 1.00
T3-4 6 3
Lymph node metastasis
N0 3 1 0.66
N1-3 5 3
Distant metastasis
M0 8 4 -
M1 0 0
TNM stage
1–2 3 1 0.66
3–4 5 3
Lymphatic vessel invasion
Negative 3 1 0.66
Positive 5 3
Venous invasion
Negative 2 1 1.00
Positive 6 3
Curability
R0 8 4 –
R1 0 0
Preoperative chemotherapy 5 3 –
Preoperative CRT 0 0
Postoperative chemotherapy 2 3 –
Postoperative CRT 0 0
Observation period (month,
mean ± SD)
64.6 ± 18.3 51.1 ± 33.6 0.049
Duration between surgery and
tumor relapse
– 8.8 ± 2.9 –
Type of tumor relapse
Liver (H) 0 2
Lymph node (Ly) 0 2
Table 4 Clinicopathological characteristics of the 12 patients in
the validation set (Continued)
miR-574-3p (<0.7) 1 3 0.029
miR-574-3p (≥0.7) 7 1
miR-106b (<1.00) 1 1 0.576
miR-106b (≥1.00) 7 3
miR-1303 (<1.20) 5 2 0.576
miR-1303 (≥1.20) 3 2
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reported to regulate “Wnt signaling” to reduce cell
proliferation by targeting epidermal growth factor recep-
tor (EGFR) expression [43]. On the other hand, this is
the first report of a correlation between the down-
regulation of miR-574-3p expression and poor prognosis
in patients with ESCC, suggesting the tumor suppressor
effects of miR-574-3p in ESCC.
Although molecular targets of miR-574-3p in ESCC
have yet to be investigated, the Wnt signaling pathway has
been reported to play an important role in progression,
metastasis, and invasion in ESCC [45]. Overexpression of
EGFR was also associated with aggressive biological be-
haviors in ESCC [46]. Accordingly, it is possible that miR-
574-3p targets the Wnt signaling pathway and/or EGFR to
suppress malignant features in ESCC as well. Investiga-
tions to reveal the biological role of miR-574-3p, such as
transfection of ESCC cell lines with miR-574-3p expres-
sion vector to assess the regulation of malignant pheno-
type, may provide us with the basis of the prognostic
significance of miR-574-3p. It may also provide us with
molecular targets to develop novel diagnostic and/or
therapeutic strategies.
In this study, we obtained formalin-fixed paraffin-
embedded (FFPE) samples of the tumors and their normal
counterparts, with adequate tissue size from 36 cases and
extracted high-quality RNA from 19 patients. After these
sample collection with technical limitation, clinicopatholog-
ical characteristics of the 19 patients summarized in Table 1
showed distinctive features compared to general population
of ESCC patients. For example, higher incidence of postop-
erative tumor relapse (14/19, 73.7 %) was seen and the
major type (9/14, 64.3 %) of the tumor relapse were
hematologic metastasis.
Therefore, it is possible that the pathological T and N fac-
tor did not correlate with postoperative tumor relapse in
our study because of the deviation in the sample collection.
Further investigations based on the large-scale collection of
samples without deviation is needed to confirm our results.
Conclusions
Our microarray analysis using the archived FFPE samples
of surgically removed ESCC tumors from 19 training set
patients identified 8 miRNAs that were differentially
expressed between the patients with and without
Fig. 4 The relationship between the expression of miRNAs (miR-574-3p, miR-106b, and miR-1303) and patient outcome in the validation cohort. a The
expression of miR-574-3p, miR-106b and miR-1303 in non-relapse and relapse groups. b The association between miR-574-3 expression and patient
prognosis. c The association between miR-106b expression and patient prognosis. d The association between miR-1303 expression and patient prognosis
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postoperative tumor relapse. The higher expression of miR-
574-3p, which showed the most significant inverse associ-
ation with postoperative tumor relapse, was significantly as-
sociated with better overall survival. Quantitative real-time
PCR experiments using frozen samples of ESCC tumors
from 12 independent validation set patients confirmed that
the higher expression of miR-574-3p was significantly asso-
ciated with non-tumor relapse and better overall survival.
Although we only examined a small number of the
cases, to the best of our knowledge, this is the first study
to show the association between the expression of miR-
574-3p and postoperative outcomes in ESCC patients.
Further investigations based on the large-scale collection
of samples are awaited to assess the clinical use of miR-
574-3p as prognostic predictor in patients with ESCC.
Molecular biological investigations to define the mecha-
nisms by which miR-574-3p suppresses malignant feature
of ESCC using cell lines also provide us with the basis of
its prognostic significance and a molecular target to
develop novel diagnostic and/or therapeutic strategies.
Additional file
Additional file 1: Table S1. The relationship between the expression of
the 20 miRNAs in the tumors (T/N ratio) and clinicopathological features
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